We determined hepatitis B virus (HBV) suppression rates among 18 lamivudine (3TC)-experienced HBV-human immunodeficiency viruscoinfected adolescents after treatment with tenofovir disoproxil fumurate (TDF). At TDF initiation, their median age was 17.6 years, and duration of 3TC exposure was 7.3 years. Eleven patients (61%) achieved HBV DNA <60 IU/mL after 48 weeks on TDF and 3TC which was similar to adult studies, although hepatitis B surface antigen loss or hepatitis B envelope antigen seroconversion did not occur.
H epatitis B virus (HBV) seroprevalence in human immunodeficiency virus (HIV)-infected children in Africa and Asia ranges from 1% to 49%
1-3 and 3% to 30%, [4] [5] [6] respectively. Among HIV-infected adults, liver disease has become a significant cause of death, accounting for one-third of mortality in the era of antiretroviral therapy (ART). 7 Because children with chronic HBV infection may transition from an immune tolerant to an immune-active phase while entering puberty or young adulthood, there was a concern regarding a life time risk of development of liver complications including hepatocellular carcinoma.
The goals of therapy are to suppress HBV replication, reduce progression of liver inflammation and ultimately to induce hepatitis B surface antigen (HBsAg) seroconversion. Tenofovir disoproxil fumurate (TDF) is recommended for treatment in HIV-HBV-coinfected adults and adolescents, 8 producing HBV virologic suppression rates ranged from 55% to 75%. [9] [10] [11] The cumulative incidence of hepatitis B envelope antigen (HBeAg) seroconversion after using TDF among adult patients with positive HBeAg ranged from 12% at 2 years 12 to 57% at 5 years of treatment. 13 TDF was approved for use in treatment of HIV-infected children as young as 2 years of age in 2012. However, it is not recommended to be used as a first-line ART in young children because of limited information on long-term safety and specific concerns about potential bone and renal toxicities. However, as part of a standard ART regimen, HBV-HIV-coinfected children receive lamivudine (3TC). 3TC is also effective against HBV but HBV resistance commonly develops after longer-term treatment. 14, 15 This study aimed to determine the rate of HBV viral suppression after receiving TDF among 3TC-experienced perinatally HBV-HIVcoinfected adolescents.
PATIENTS AND METHODS
A prospective open label longitudinal treatment study was conducted at 5 referral centers in Thailand: Research Institute for Health Sciences, Chiang Mai University; The HIV Netherlands Australia Thailand Research Collaboration, the Thai Red Cross AIDS Research Centre, Bangkok; Chiang Rai Prachanukroh Hospital, Chiang Rai; Khon Kean University Hospital (KKU), Khon Kean, and Nakornping Hospital, Chiang Mai. Inclusion criteria were (1) HIV-infected adolescents 12-25 years of age, (2) chronic HBV infection, defined by the persistence of HBsAg for more than 6 months and (3) exposure to 3TC. Those with exposure to TDF or liver disease other than HBV infection were excluded. The study protocol was approved by ethic committees at each site. For study participants < 18 years of age, written informed consent was obtained from caregivers and assent form participants; participants older than age 18 years provided consent for themselves.
At study entry, the antiretroviral regimens were modified to include both TDF and 3TC. TDF 300 mg tablet and 3TC 150 or 300 mg tablet were used. HBV DNA level and liver function tests were measured at baseline and weeks 12, 24 and 48 after receiving TDF. HBsAg, HBeAg, anti-HBe and anti-HBs were measured at baseline and week 48. Blood for hepatitis profile was collected and processed at the site before shipping to The HIV Netherlands Australia Thailand Research Collaboration laboratory for testing. HBsAg, hepatitis B envelope antigen, anti-HBs and anti-hepatitis B envelope antigen were measured by Abbott AxSYM, microparticle enzymatic immunoassay), with limit of detection of 10-300 U/mL. HBV DNA was measured by Abbott real-time (polymerase chain reaction assay), with limit of detection of 10-10 9 IU/mL. Alanine aminotransferase (ALT) testing was performed at each site.
The primary outcome measure was the rate of HBV virologic suppression at week 48. HBV virologic suppression was defined as HBV DNA < 60 IU/mL (equivalent to 300 copies/mL). HBV-HIV-coinfected adolescents were categorized into 3 groups according to HBV DNA level 16 : high-level viremia, HBV DNA level > 5.0 log10 IU/mL; low-level viremia, HBV DNA 60-5.0 log 10 IU/mL and inactive state, HBV DNA < 60 IU/mL. While for treatment purposes, 20,000 IU/ml (4.3 log 10 IU/mL) is usually used as cutoff of treatment of HBV monoinfected patients, most natural history outcome studies have defined high HBV viral load using a 200,000 IU/ml (5.3 log 10 IU/mL) cutoff. In this study, we define high-level viremia as having HBV DNA level > 5.0 log 10 IU/ mL, which resulted in no difference when using cutoff at either 4.3 or 5.3 log 10 IU/mL because of there was no case with HBV DNA levels between the two cutoff. The normal values from the Harriet Lane Handbook (19th edition) were used as a reference. 17 The cutoff for abnormal ALT was > 30 IU/mL which is the upper range for female 12-16 years of age, was used for all age participants in this study to make it simple and sensitive. ALT > 3× ULN was suggestive of the presence of liver inflammation, and hepatic flare was defined as ALT > 5× ULN.
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Statistical analysis was performed using SPSS version 22.0 (IBM Corporation, Armonk, NY). Continuous variables were presented as mean [standard deviation (SD)] or median (range or interquartile range), as appropriate. Analysis was performed on both intention-to-treat basis in which missing values were categorized as not achieved HBV virologic suppression and as-treated basis in which only participants who remained on study were counted. A P value of <0.05 for two-sided tests was considered to be statistically significant.
RESULTS
From March 2012 to March 2014, 18 HIV-infected adolescents and young adults at median (range) age of 17.6 (12.9-21.9) years were enrolled; 8 (44%) were male. Their median ages at the time of HIV diagnosis and ART initiation were 8.6 years (range 1.4-14.9) and 9.4 years (range 2.0-16.0), respectively. Before ART, 7 (39%) were in World Health Organization stage 3 or 4, and 15 (83%) were severely immune suppressed [having either CD4 T-lymphocyte (CD4) percentage < 15% for age < 5 years or CD4 count < 200 cells/mm 3 for age ≥5 years]. In the 4 (22%) patients who had HIV RNA level measured before ART, values ranged from 4.9 to 5.9 log10 copies/mL. Fifteen (83%) received 3TC as a part of their first-line ART regimen. Five (28%) were diagnosed as HIV-HBV coinfection before the age of 12 years. The median age at HBV diagnosis and duration on 3TC exposure before study entry were 14.6 (4.3-20.4) and 7.3 (0.7-11.1) years, respectively. At the time of study entry, the median (range) CD4 count was 650 (334-912) cells/mm 3 ; 83% had HIV RNA level <40 copies/mL. There were 13 (72%), 3 (17%) and 2 (11%) adolescents who had high-level HBV viremia, low-level HBV viremia and inactive state, respectively ( Table 1) . Six of 7 cases (86%) with available HBV genotyping had evidence of 3TC-associated resistance mutations (YVDD or YIDD).
The median (range) HBV DNA reductions at weeks 12, 24 and 48 are shown in Table 1 . By intention-to-treat analysis among the 16 patients with either high-or low-level HBV viremia, the proportion of adolescents with HBV virologic suppression at weeks 12, 24 and 48 were 6%, 19% and 56%, respectively. Among 13 adolescents with high-level HBV viremia, 7/13 (54%, intention-to-treat) and 7/11 (64%, as treated) achieved HBV virologic suppressed at week 48, whereas the other 4 patients had low HBV DNA levels ranging from 286 to 558 IU/mL. A significant decline in HBV DNA levels was observed. Among 13 patients with high-level viremia, the median HBV DNA reductions were 3 before ART initiation, had received 3TC for 5.4 years and had a 3TC resistance mutation (YVDD) detected in the past before at the study entry when her HBV DNA was detectable; the other, age 18.7 years, was severely immunosuppressed before ART, had received 3TC for 8.7 years (no 3TC resistance testing was performed) and had HBsAg loss at week 48 without development of anti-HBs.
Of 18 adolescents with baseline ALT, 3 (17%) had ALT > 30 U/L (range 34-56 U/L). All had ALT higher than baseline at week 24 (range 68-88 U/L). One had ALT decrease to 31 U/L at week 48, 1 was lost to follow-up, and another had ALT 86 U/L with HBV DNA decrease −4.56 log from baseline, but did not achieve HBV DNA suppression (Fig. 1C) . Among those with baseline ALT < 30 U/L, 6 had ALT increase at week 12 ranging from 38 to 129 U/L (only 1 had ALT > 3× ULN which subsequently decreased to <30 U/L). The other 2 had ALT increase at week 24 but <3× ULN; 1 persisted until week 48, and 1 decreased to <30 U/L. None had ALT > 5× ULN.
DISCUSSION
In this study, we demonstrated that TDF was effective in suppressing HBV virus in our study of HBV-HIV-coinfected Asian adolescents with prior long-term exposure to 3TC. The HBV virologic suppression rate at week 48 was 61%. This information is reassuring for settings where HBV coinfection is detected later in the course of HIV treatment and for coinfected infants and young children who require HIV treatment before they are old enough to receive TDF.
The first-line ART used in HIV-infected children in low-and middle-income settings almost always includes 3TC, which could put HBV-HIV-coinfected children at risk of developing HBV resistance after a few years of treatment. 18 The World Health Organization 2013 guidelines (updated November 2015) recommend using TDF and 3TC as a part of preferred regimen for ART-naïve HIVinfected patients older than 10 years of age, and also those with HBV coinfection and severe chronic liver disease. 19 For adolescents from 10 years of age to adults who were already on ART, modifying the ART regimen to replace TDF for other drugs (eg, zidovudine) is advised to increase long-term efficacy of HBV cotreatment. We reported a favorable outcome on HBV viral suppression in this population, which is comparable to previous studies in HBV-HIVcoinfected adults. 10, 11 In our study, the treatment response among the group with high-level viremia was 54% at week 48, which is comparable with a report in German adults where 55% of patients with high-level HBV viremia (defined as HBV DNA > 6.0 log 10 copies/mL) achieved HBV DNA < 200 copies/mL at week 48. 10 A Thai study using TDF and 3TC in ART-naïve HBV-HIV-coinfected adults reported 64% HBV virologic suppression at 48 weeks after treatment initiation. 11 The incidence of HBV virologic suppression tends to increase with time, as shown in a systemic review and meta-analysis from 23 studies using TDF in HBV-HIV-coinfected adults. 20 The overall HBV suppression rates were 57.4%, 79.0% and 85.6% at 1, 2 and 3 years on treatment, respectively.
None of our patients had HBeAg seroconversion during 48 weeks of follow-up. This might be explained by the duration of study follow-up or high baseline HBV DNA levels. This was unexpected, as there was a report that 31% of HBV-HIV-coinfected Thai adults had HBeAg seroconversion after a year on TDF-based regimens. 11 Another study from Austria reported that 8%-10% and 50%-57% of adults with coinfection had HBeAg seroconversion at 1 and 5 years of treatment. 13 The study in HBV monoinfected adolescents treated with TDF reported that 89% had HBV DNA < 400 copies/mL at week 72, with HBeAg and HBsAg loss in 21% and 2%, respectively. 21 The better treatment response in their study than ours may have been the absence of HIV coinfection, acquisition of HBV infection after the perinatal period and high rate (71%) of interferon use before treatment with TDF.
None of the adolescents in our study developed hepatic flare; we observed only transient ALT elevations. A previous Thai study reported that 25% of HBV-HIV-coinfected adults experienced hepatic flare during first year of TDF treatment. 11 However, their patients had advanced HIV disease with very low CD4 counts. Concomitant use of other potentially hepatotoxic agents at the time of study, immune reconstitution syndrome following treatment initiation, as well as HBV immune activation itself could be explanations for the hepatic flares observed in their study. In contrast, the low incidence of ALT elevation observed in our study might be because of the adolescents being on stable ART, with good immune status. Moreover, some of them might not yet have transitioned from immune tolerance to the immune-active phase of HBV infection. The long-term follow-up of this study is underway to assess the HBsAg and HBeAg seroconversion rate and assessment of liver inflammation and fibrosis.
Limitations of this study include the small sample size, the use of qualitative methods for HBeAg and HBsAg which did not permit quantification of change, and lack of treatment adherence measurement, which might account for nonsuppression in certain adolescents and young adults. The rationale for not using traditional classification of HBV immune phase was that several of our patients' profile did not match the definition of each immune category, that is, having high viremia and increase ALT, or HBeAg positive with undetectable HBV DNA. This might be because of previous use of 3TC, as the traditional classification is for HBV treatment naive population. Thus, we decided to go with categorization by level of HBV viremia as presented. This limited direct comparison of our study results with other HBV studies in children.
More than 70% of subjects had high-level HBV 3TC resistance at baseline from long-term exposure to 3TC alone, consistent with data from studies of adults with HBV infection. However, the addition of TDF to the ART regimen led to rapid and almost complete HBV suppression in almost all patients despite 3TC resistance. These findings provide reassurance that HBV-HIV-coinfected infants and young children can initiate standard, age-appropriate first-line ART that includes 3TC but not TDF until they are old enough to have TDF incorporated into their ART regimen without compromising their chances for achieving HBV virologic suppression.
In conclusion, using TDF among HBV-HIV-coinfected adolescents with prolonged prior 3TC exposure was associated with favorable levels of HBV viral suppression at week 48. Longer-term follow-up is needed to better document the potential for HBeAg seroconversion and HBsAg loss.
